Author:
Yoshimaru Tetsuro,Komatsu Masato,Tashiro Etsu,Imoto Masaya,Osada Hiroyuki,Miyoshi Yasuo,Honda Junko,Sasa Mitsunori,Katagiri Toyomasa
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Johnston, S. R. New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 16, 1979–1987 (2010).
2. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 97, 1652–1662 (2005).
3. Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine. Nature Rev. Drug Discov. 2, 205–213 (2003).
4. Clarke, R., Leonessa, F., Welch, J. N. & Skaar, T. C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53, 25–71 (2001).
5. Fisher, B., Dignam, J., Bryant, J. & Wolmark, N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl. Cancer Inst. 93, 684–690 (2001).
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献